Introduction
Impaired insulin signaling is a physiological condition that cells lost the ability to respond to insulin. This failure to respond is called insulin resistance and plays a central in the development of the metabolic disorders such as diabetes, obesity, hypertension, and dyslipidemia. Particularly, defective brain insulin signaling has been implicated in the development of Alzheimer's disease (AD), the most common cause of dementia [1] . In fact, abnormal insulin sensitivity is shown to be associated with AD-related pathological features. For example, type 2 diabetes (T2D) is identified as a major risk factor for AD, suggesting defective insulin signaling may account for pathogenesis of neurodegeneration [2] . Moreover, patients with AD show significantly reduced expression of insulin receptors and insulin receptor substrate (IRS) in the brain that contributes to the severity of cognitive impairment [3] . All these findings suggest that neuronal insulin signaling is altered in the AD brain resembling T2D [4] . Actually, AD pathogenesis is initially triggered by the presence of extracellular amyloid-b (Ab) proteins, which are found to cause oxidative stress and neurotoxicity in the brain [5] . It is well known that insulin and its receptors are widely expressed in neurons and glial cells throughout the brain [6] , and evidence is also presented that insulin can be produced locally within the brain [7] . In addition, Ab has been reported to impair synaptic insulin sensitivity in cultured neurons, which may impair synaptic functions associated with pathogenesis of AD [8] . This indicates insulin signaling may serve as an important regulatory role in neurons. However, the molecular basis that links between insulin signaling and Ab-induced neurotoxicity remains unclear.
At a molecular level, the serine phosphorylation of insulin receptor substrate (IRS) can block the insulin signaling. This results in the inhibition of IRS tyrosine phosphorylation, suppressing the downstream phosphatidylinositol 3-kinase (PI3-kinase) signaling and subsequent inactivation of the kinase Akt [9] . It is known that activated Akt inactivates glycogen synthase kinase 3b (GSK3b) by phosphorylating its Ser 9 residue, which is one of the important enzymes induce tau hyperphosphorylation and neurotoxicity [10] . For this reason, impairment of insulin signaling may result in a high activity of GSK3b, which leads to an enhanced tau hyperphosphorylation, a crucial step in AD pathogenesis. Hyperphosphorylated tau and Ab cooperatively impair mitochondrial membrane potential and further increase in accumulation of intracellular reactive oxygen species (ROS), which ultimately result in neurodegeneration [11] . Therefore, it is not surprising that pharmaceuticals found to be effective treatment of impaired insulin signaling have also shown benefits in the prevention or reduction of AD [12] . The enzyme dipeptidyl peptidase-4 (DPP-4) is a ubiquitous membrane-bound prolyl peptidase that was responsible for the degradation of incretin hormones [13] . Incretins are a group of gut-derived hormones that potentiate insulin secretion and related cellular signaling [14] . However, incretins are rapidly metabolized and inactivated by DPP-4. As a result, DPP-4 inhibitors such as linagliptin have a relevant effect of increasing the half-life in retaining the physiological effects of endogenous incretins [15] . Interestingly, it has been recently shown that incretins may be good candidates for treating AD [16] . For example, glucagon-like peptide-1 (GLP-1), the major incretin in humans, has been shown to elicit neuroprotective properties against AD pathological processes [17] . Similar to insulin, GLP-1 is produced in the brain mediating many neuronal functions, including neuroprotection, improvement of learning and memory ability, and potentiation of insulin signaling [18] . Therefore, GLP-1 signaling have demonstrated the potential to serve as therapeutic or preventive strategies against diabetes-related AD [19] . As DPP-4 inhibitor effectively increases GLP-1 levels, it may also exert protective effects against AD-related Ab-induced neurotoxicity. Linagliptin is a recently approved DPP-4 inhibitor and widely considered as the first-line treatment for T2D patients. It has been demonstrated greater inhibitory effects than other DPP-4 inhibitors such as alogliptin, saxagliptin, sitagliptin, or vildagliptin [20] . Moreover, linagliptin also significantly improves insulin secretory dysfunction and sensitivity in animal studies [21] . This indicates linagliptin may have beneficial effects on impaired insulin signaling in neuronal cells. However, whether linagliptin is involved in Ab-induced neurotoxicity is still largely unknown. In this study, we postulated that neuronal insulin resistance may be one of the underlying neurotoxic mechanisms by Ab, whereas linagliptin can protect neuronal cells by restoring impaired insulin signaling, and thereby contribute to the alleviation of Ab-induced neurotoxicity.
Materials and Methods

Materials
Chemicals such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 4 0 ,6-diamidino-2-phenylindole (DAPI), and JC-1 were purchased from Sigma (M€ unchen, Germany 
Cell Culture and Viability Assay
Human neuroblastoma SK-N-MC cells were obtained from the American Type Culture Collection (Bethesda, MD, USA). Cells were maintained in minimal Eagle's medium (MEM; Gibco, Carlsbad, CA, USA), supplemented with 10% fetal calf serum, 100 units/mL penicillin, 100 lg/mL streptomycin, and 2 mM Lglutamine at 37°C, 5% CO 2 . The Ab solutions were prepared as described previously [22] . 
Western Blot Analysis
After treatment, cells were harvested and homogenized in a protein extraction lysis buffer (50 mM Tris-HCl, pH 8.0; 5 mM EDTA; 150 mM NaCl; 0.5% Nonidet P-40; 0.5 mM phenylmethylsulfonyl fluoride; and 0.5 mM dithiothreitol), and centrifuged at 12,000 g for 30 min at 4°C. The supernatants were used as cell extracts for immunoblotting analysis. SDS-solubilized samples were then loaded onto SDS-polyacrylamide gels. Equal protein amounts of total cell lysates were resolved by 10% SDS-PAGE, transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA), and then probed with a primary antibody followed by a secondary antibody conjugated with horseradish peroxidase. The immunocomplexes were visualized with enhanced chemiluminescence kits (Millipore). The relative expression of proteins was quantified densitometrically by using the software QuantityOne (BioRad, Hercules, CA, USA) and was calculated according to the reference bands of b-actin. Each blot represents at least in three independent experiments.
Microscopic Observation and Nucleus Morphology
Changes in cell nucleus morphology, characteristic of apoptosis, were examined in cells grown on coverslips, using a microscope. The cells were fixed in 4% paraformaldehyde after 24 h of treatment with the indicated compounds. For phase-contrast inverted microscopy, images of cells were captured with no specific staining procedure. For nucleus morphology microscopy, cells were fixed in ice-cold methanol, and incubated for 15 min at room temperature with 1 ng/mL of 4 0 ,6-diamidino-2-phenylindole (DAPI) stain, and observed under a fluorescence microscope (DP80/BX53; Olympus, Tokyo, Japan). Apoptosis was quantified by averaging cell counts in twenty random 4009 fields. Values were expressed as the percentage of apoptotic cells relative to total number of cells.
Measurement of Reactive Oxygen Species
To evaluate the levels of intracellular ROS, cells were seeded onto glass coverslips and incubated with 10 lM of 2 0 , 7 0 -dichlorodihydrofluorescin diacetate (DCFH-DA, a general oxidative stress indicator) for 0.5 h at 37°C under 5% CO 2 after treatment. After incubation, the staining medium was discarded and cells were washed twice with immediately with PBS, after which the intensity of fluorescence was imaged by a fluorescence microscopy (DP72/CKX41; Olympus) using an excitation wavelength of 488 nm and an emission wavelength of 525 nm. One representative image of three different experiments is shown.
Analysis of Mitochondrial Membrane Potential
The vital mitochondrial cationic dye JC-1, which exhibits potential-dependent accumulation in mitochondria, was used to investigate mitochondrial function. Cells were treated in fresh medium containing 1 lM JC-1 and were incubated at 37°C for 30 min. The staining medium was then discarded and the cells were washed. Cells then imaged using an inverted fluorescence microscope (DP72/CKX41; Olympus) excited at 488 nm. In normal cells, JC-1 continues to exist as aggregates and produces a red fluorescence (~590 nm). During the induction of apoptosis, the mitochondrial potential collapses and JC-1 forms a monomer producing green fluorescence (~525 nm). 
Blood Samples from Patients
Statistical Analysis
All data are presented as means AE standard error of the means (SEM). Statistical analysis of data was performed using analysis of variance (ANOVA), followed by Dunnett's post hoc test for multiple comparisons with SPSS statistical software (SPSS, Inc., Chicago, IL, USA). Differences were considered statistically significant at P < 0.05.
Results
Effects of Linagliptin on Viability of SK-N-MC Neuronal Cells
The influence of DPP-4 inhibitor linagliptin treated in neuronal cells is largely unknown. To evaluate the effects of linagliptin on cell viability, SK-N-MC neuronal cells were exposed to 10 to 100 lM of linagliptin for 24 h, and the cytotoxic effects were determined by MTT assay ( Figure 1A) . The results showed that linagliptin concentrations ranging from 10 to 50 lM did not induce significant cytotoxicity, whereas treatment with 100 lM linagliptin slightly reduced cell viability. In accordance, treated with 50 lM of linagliptin displays no significant time-dependent change within a 48-h period ( Figure 1B ). This indicates no detectable toxic effect is present at a concentration <50 lM of linagliptin. Thus, in subsequent experiments, we investigated the mode of action of linagliptin at a concentration of 50 lM. It is known 
Linagliptin Protects SK-N-MC Cells Against Abinduced Neurotoxicity
Recent studies have demonstrated the DPP-4 inhibitory properties indicating neuroprotective effects against AD pathological hallmarks such as Ab accumulation, tau phosphorylation and neuroinflammation [23] . To assess whether linagliptin exerts these similar beneficial effects, cell viability assay was conducted to determine the neuroprotective effect of linagliptin on Ab-induced cell death. As shown in Figure 2A , incubation of SK-N-MC cells with 2.5 lM of Ab for 24 h markedly underwent a~50% decrease of MTT reduction. However, linagliptin alleviated cell death at concentrations ranging from 10 to 50 lM of SK-N-MC cells in a dose-dependent manner during Ab treatment. To precisely determine which mode of cell death is induced by Ab, we examined the expressions of cleaved caspase 3 and poly (ADPribose) polymerase (PARP), two typical markers of apoptosis by western blotting. As shown in Figure 2B , Ab markedly increased cleavage of caspase 3 and PARP, indicating the enhanced apoptosis occurs mainly in Ab treatment. On the contrary, co-treated with linagliptin was shown to effectively inhibit caspase 3 and PARP activation by Ab. These results were also confirmed by DAPI staining that treatment with linagliptin significantly reduced nuclei fragmentation as shown in Figure 2C . Taken together, this support the idea that the addition of linagliptin may effectively attenuate Ab-induced apoptosis in neuronal cells.
Linagliptin Restores Ab-induced Insulin Signaling Blockade in Neuronal Cells
Because the mechanism of DPP-4 inhibitors is to increase endogenous incretin levels, we proposed that linagliptin might exert Figure 3B ). Several lines of evidence have indicated that linagliptin can enhance insulin action and plays an important role in improving insulin sensitivity in peripheral tissues [24] . To further elucidate the molecular mechanism of linagliptin-mediated neuroprotection, Western blot analysis was conducted to detect the levels of phospho insulin receptor substrate-1 (IRS-1) at residue Ser 307 and Tyr in SK-N-MC cells. As shown in Figure 3C , Ab treatment for 24 h caused a significant increase in Ser 307 IRS-1 phosphorylation, which is recognized as a hallmark of insulin resistance. Accordingly, Ab also prevented IRS-1 phosphotyrosine (4G10 clone) expression. By contrast, co-treated with linagliptin returned the Tyr phosphorylation of IRS-1 and its downstream target Akt to basal levels, showing that the neuronal insulin signaling can be activated by linagliptin during Ab treatment. To gain insight into the downstream effects of Akt in the presence of linagliptin, we investigated the glycogen synthase kinase 3b (GSK3b), a direct phosphorylation target of Akt. After 24 h of Ab treatment, the Ser 9 phosphorylation of GSK3b was markedly inhibited, which indicates the Absuppressed Akt pathway leads to activation of GSK3b ( Figure 3D ). However, linagliptin could reduce GSK3b activity by increasing Akt-mediated GSK3b Ser 9 phosphorylation during Ab treatment.
This linagliptin-mediated neuroprotection was also confirmed by inhibiting Thr 231 phosphorylation of one GSK3b's downstream substrate tau, which was recognized as one of the crucial pathological hallmarks of AD. To further investigate the role of insulin , and glucagon-like peptide 1 (GLP-1) are measured by using real-time qPCR, and the results are presented as means AE standard error of the means (SEM) of three independent experiments. *P < 0.05 and **P < 0.01 by using multiple comparisons of Dunnett's post-hoc test. N. S., no significant difference.
signaling in linagliptin-mediated neuroprotection, the PI3-kinase inhibitor LY294002 was used as negative control. As shown is Figure 3D and 3E, LY294002 significantly blocked the linagliptinrestored Akt signaling and cell viability during Ab treatment. This indicates that Ab-impaired insulin signaling may trigger neuronal apoptosis; however, linagliptin effectively reduces Ab-induced cytotoxicity by returning the blocked neuronal insulin signaling.
Linagliptin Protects Cells Against Ab-Induced Intracellular ROS Accumulation and Mitochondria Dysfunction
Previous studies show strong evidence that Ab-induced ROS accumulation and mitochondrial dysfunction are both potential pathogenic markers in AD [25] . To determine whether linagliptin protects cells from Ab-induced oxidative stress, we measured intracellular ROS levels by a 2 0 ,7 0 -dichlorofluorescin diacetate (DCFH-DA) fluorometric method. As expected, our results showed that linagliptin suppresses Ab-induced ROS intracellular accumulation, which in turn protects cells from oxidative stress ( Figure 4A ). It is also suggested that increased ROS levels may inhibit AMP-activated protein kinase (AMPK) activity, which is likely to promote the development of insulin resistance [26] . To test whether such mechanism is also involved in SK-N-MC cells, the phosphorylation of AMPK was determined by immunoblotting in Figure 4B . Our results showed that Ab significantly downregulates the Thr 172 phosphorylation of AMPK, whereas this effect was counteracted by co-treatment of linagliptin. Further- Other data were performed in three independent experiments, and values are presented as mean AE SEM. Significant differences was determined by using the multiple comparisons of Dunnett's post-hoc test for *P < 0.05 and **P < 0.01 compared to Ab only groups. Scale bar represents 50 lm. more, western blot analysis of AMPK downstream target sirtuin 1 (Sirt1) and superoxide dismutase 1 (SOD1) protein expressions also provided evidence that levels of these antioxidative pathways are increased significantly by linagliptin compared to Ab only groups. As discussed previously, the pathogenic role of Ab in mediating ROS accumulation was often accompanied by mitochondrial dysfunction. To further examine the details of linagliptin-mediated neuroprotection, we performed JC-1 staining to assess the mitochondrial membrane potential. As shown in Figure 4C , JC-1 aggregates were found in healthy mitochondria by a red fluorescence in nontreated controls. However, exposure of cells to Ab resulted in significant increases in green fluorescence, indicating a loss of mitochondrial membrane potential. On the contrary, co-treatment with linagliptin reduced the deteriorating effects of Ab on mitochondrial membrane potential. We further confirmed that insulin signaling inhibition results in an oxidative stress damage by Ab, as the PI3-kinase inhibitor LY294002 significantly attenuated linagliptin-mediated antioxidative effects, suggesting these benefits may depend on linagliptin-improved insulin sensitivity in neuronal cells.
Peripheral Blood Leukocyte Sirt1 mRNA Expression is Partially Returned by Linagliptin in Diabetic Patients with AD
Sirt1 is an important modulator in humans in the protection against oxidative events. A previous study reported that the Sirt1 mRNA expression level is suppressed in blood samples obtained from patients with AD or T2D [27, 28] . However, it remains unclear whether the reduction of Sirt1 mRNA is more susceptible to diabetic patients with AD. To evaluate Sirt1 inhibition in diabetic AD patients, peripheral leukocytes were isolated and Sirt1 mRNA levels were determined with fourteen human subjects with clinically diagnosed AD (six pure AD, four diabetic AD without linagliptin treatments, and four diabetic AD with linagliptin treatments at least for 6 months). A detailed overview of the patient's characteristics is summarized in Table 1 . In line with our preliminary expectation, both mini-mental state examination (MMSE) scores and Sirt1 mRNA expressions were lower in patients with diabetic AD as compared to pure patients with AD. However, the MMSE scores and expressions of Sirt1 mRNA were significantly , a specific inhibitor of PI3-kinase. All data were performed in three independent experiments, and values are presented as mean AE SEM. Significant differences was determined by using the multiple comparisons of Dunnett's post-hoc test for *P < 0.05 and **P < 0.01. Scale bar represents 20 lm.
restored in diabetic patients with AD treated with linagliptin (Table 1 ). This observation consists the idea that patients with diabetic AD expressed reduced Sirt1 by inhibition of incretin signaling, which may contribute to pathogenesis of neurodegeneration.
Discussion
Interestingly, accumulating evidence indicates a strong link between T2D and AD, highlighting the key role of insulin signaling in the pathogenesis of these diseases. Although the underlying mechanism remains largely unknown, now the evidence for it has become very significant [29] . In fact, Steen et al. have firstly proposed a connection between increased insulin resistance in the brain with AD and termed it as "type 3 diabetes" [30] , hinting that insulin-based therapies may be useful in the treatment of AD. Traditionally, the majority of insulin in the brain is generated from pancreatic b-cells and transported across the blood-brain barrier (BBB). However, insulin can be locally synthesized and released by neurons [31] . Moreover, GLP-1 and its receptor are also known to ubiquitously express in central nervous system (CNS), particularly in hypothalamus, cortex and hippocampus that typically vulnerable in patients with AD [32] . Therefore, it is not surprising [33] , it is possible that DPP-4 inhibitors such as linagliptin may represent a promising strategy against Ab-induced neurodegeneration. Insulin resistance and mitochondrial dysfunction are the two common features both in AD and T2D [34] . As previous mentioned, mitochondrial dysfunction leads to impairment of insulin sensitivity by reduced activity of AMPK, an important cellular fuel sensor and regulator [35] . Ab was found to cause ROS accumulation and oxidative damage in the brain, which is believed to play a pivotal role in the development of insulin resistance [36] . Interestingly, GLP-1 has been reported to stimulate AMPK activation in preventing the ROS production and vice versa [37] . Additionally, AMPK activation has also been suggested to enhance insulin sensitivity by GLP-1 agonist liraglutide [38] . This indicates that AMPK may play a key role in response to Ab exposure by DPP-4 inhibition. In accordance with these findings, we found that the Thr 172 phosphorylation of AMPK could be reduced during the incubation of cells with Ab, and this inhibition was prevented by linagliptin co-treatment. Moreover, we also observed that linagliptin protects mitochondrial function and suppresses intracellular ROS accumulation depends on insulin signaling pathways. These observations were further confirmed by Sirt1, a well-known longevity factor, is in fact upregulated by linagliptin. By linagliptin treatment, AMPK can trigger its downstream target Sirt1, which was reported previously in triggering antioxidant pathways such as SOD [39] . Considering the important roles of the Ab-induced oxidative stress in AD pathogenesis, our research unveils a new neuroprotective mechanism by which linagliptin suppresses oxidative damage and preserves mitochondria function through restoration of neuronal insulin signaling.
Recently, Kosaraju et al. [40, 41] observed that inhibition of DPP-4 ameliorates streptozotocin-induced memory loss and neuronal death in rats, indicating the possibility of using of these agents for the treating diabetes-associated AD. Their results revealed a significant improvement in a dose-dependent attenuation of Ab production, tau hyperphosphorylation and cognitive deficits by upregulation of GLP-1 signaling. These robust therapeutic effects of DPP-4 inhibitors demonstrate a unique mechanism for Ab-related pathology observed in AD. However, previous study has demonstrated that linagliptin does not pass through the BBB easily [42] , whereas GLP-1 could be able to effectively penetrate into the brain [43] . Because linagliptin has been suggested to have direct neuroprotective effects, we postulate that linagliptin treatment may increase levels of brain blood GLP-1 and confers its neuroprotection. This is further supported by the fact that linagliptin-mediated neuroprotection occurs directly at the neuronal level because the brain expression of GLP-1 receptors is exclusively in neurons [44] . However, further evaluation is necessary to confirm the neuroprotective effect of linagliptin in patients with AD. Collectively, in the present study we provided evidence for the view that linagliptin inhibits neurotoxicity induced by Ab. This protection appears to be associated with the insulin signaling-dependent AMPK activation and the Sirt1-elicited antioxidant pathways such as SOD1. To our knowledge, this is the first report demonstrating the AMPK-Sirt1 molecular mechanism of linagliptin against Abinduced insulin signaling impairment and oxidative damage. Our report therefore provides new insights that incretin-based agents such as linagliptin may be a potential useful therapeutic approach to AD.
